Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) canceled its previously scheduled first quarter 2026 earnings conference call and webcast for May 12, 2026 at 8:30 AM ET because of a pending acquisition by Angelini Pharma S.p.A. The company will release Q1 2026 results after market close on Monday, May 11, 2026.
The cancellation removes the live Q&A session; financial results will still be published as planned on May 11.
Positive
- Q1 2026 results will be released after market close on May 11, 2026
- Company cites pending acquisition by Angelini Pharma as reason for call cancellation
Negative
- Cancelled earnings call and webcast scheduled for May 12, 2026 at 8:30 AM ET
- Investors lose live Q&A opportunity tied to the May 12 webcast
The Company will Report First Quarter 2026 Financial Results on May 11, 2026
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today.
Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2025 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC (646) 249-6817 Ignacio.Guerrero-Ros@russopartnersllc.com